NATCO Pharma Limited (NATCOPHARM) AI Stock Analysis

• Market Cap: ₹171.50B
• Dividend Yield: 0.57%
• Average Volume (3M): 59.22K
• Price to Earnings (P/E): 26.7
• Beta (1Y): 1.03
• Revenue Growth: -3.79%
• EPS Growth: -20.88%
• Country: IN
• Employees: 4,016
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 8.46
• Shares Outstanding: 179,109,860
• 10 Day Avg. Volume: 63,709
• 30 Day Avg. Volume: 59,218
• PEG Ratio: 0.21
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 3.25
• P/FCF Ratio: 10.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 74.51
• Revenue Forecast (FY): ₹40.51B

• Rating: 76 Outperform
• Price Target: ₹1,149.00 ▲(28.62% Upside)
• Action: Reiterated Date: 11/28/25
• Date: Action: Reiterated 11/28/25

NATCO Pharma Limited's strong financial performance and positive technical indicators are the primary drivers of its stock score. The company shows robust revenue growth and profitability, supported by a solid balance sheet. Technical analysis indicates bullish momentum, although caution is advised due to near-overbought RSI levels. The valuation is attractive, making the stock appealing for potential investors.

Positive Factors

Balance sheet strength

Minimal financial leverage and a high equity ratio provide durable financial flexibility for regulatory filings, R&D or targeted M&A. A near-25% ROE indicates effective capital allocation, supporting long-term shareholder value and resilience through cyclical pharma pressures.

Strong cash generation

Robust FCF growth and almost one-to-one operating cash conversion mean the business can fund launches, compliance and capacity from internal cash. Consistent cash conversion reduces reliance on external financing and supports durable reinvestment and dividend optionality.

High margins and operational efficiency

Elevated gross and operating margins alongside double-digit revenue growth point to differentiated or complex generics and efficient manufacturing. Sustained margin advantage supports scalability across markets and long-term profitability even with pricing or mix shifts.

Negative Factors

Earnings volatility (EPS decline)

A negative EPS growth rate indicates potential earnings volatility from timing of launches, one-offs, or operational headwinds. Persistent EPS declines would weaken confidence in sustainable earnings power and could constrain reinvestment despite healthy reported margins.

Dependence on partner-led launches

Heavy reliance on licensing and commercialization partners for regulated markets reduces control over launch timing, pricing and captured economics. Long-term growth and margin sustainability depend on partner execution and contract terms, limiting visibility and predictability.

Capex pressure risk

Management caution on capex implies upcoming or ongoing investment needs (capacity, compliance, approvals). Higher-than-expected capex could erode free cash flow and financial flexibility, offsetting current strong cash generation and pressuring long-term reinvestment plans.

NATCO Pharma Limited Business Overview & Revenue Model

Company Description

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

How the Company Makes Money

NATCO Pharma makes money mainly by selling pharmaceutical products and by monetizing intellectual property/market access through partnerships. Key revenue streams typically include: (1) Formulations sales: Revenue from finished dosage medicines sold in India and exported to international markets. This can include both branded generics in the domestic market and generic products supplied to regulated markets via partners or through its own commercialization where applicable. (2) API sales: Revenue from manufacturing and supplying active pharmaceutical ingredients to other pharmaceutical companies and for internal captive use; APIs may be sold under long-term supply relationships depending on the product. (3) Collaboration, licensing, and profit-sharing income: For certain complex or high-value generics, NATCO often works with marketing partners (especially for regulated markets). Depending on the arrangement, NATCO may earn milestone-style receipts, license fees, supply revenue, and/or a share of profits from product launches. (4) Other operating income: This can include contract manufacturing or services if and when undertaken, and may also include product-specific settlements or one-time receipts related to intellectual property disputes; if present, these are typically non-recurring and can meaningfully affect earnings in a given period. Overall profitability is driven by the mix of high-margin specialty/complex generics, the timing of launches in regulated markets (often via partners), volumes and pricing in India, and manufacturing efficiency across formulations and APIs.

NATCO Pharma Limited Financial Statement Overview

Summary

NATCO Pharma Limited demonstrates strong financial health with robust revenue growth, high profitability margins, and a solid balance sheet. The company effectively converts earnings into cash and maintains low leverage, indicating financial stability. However, attention is needed on capital expenditures and managing liabilities to ensure sustained performance.

Income Statement

NATCO Pharma Limited shows strong income statement performance with notable revenue growth of 10.7% from 2024 to 2025. The company's gross profit margin is robust at 65.7%, and the net profit margin stands at a healthy 42.6%. The EBIT margin of 44.3% and EBITDA margin of 57.6% in 2025 reflect efficient cost management and strong operational performance. However, a slight decline in gross profit from 2024 indicates a need for careful monitoring.

Balance Sheet

NATCO Pharma Limited has a strong balance sheet with a low debt-to-equity ratio of 0.04, indicating low financial leverage. The return on equity is impressive at 24.8%, showcasing effective use of shareholders' funds. The equity ratio is robust at 88.1%, emphasizing financial stability. However, a decrease in gross profit and increasing liabilities over the years highlight potential areas of concern.

Cash Flow

The cash flow statement highlights strong free cash flow growth of 67.4% from 2024 to 2025, indicating improved cash-generating capability. The operating cash flow to net income ratio of 0.97 suggests efficient conversion of profits into cash. Furthermore, the free cash flow to net income ratio of 0.76 reflects effective cash management. Despite the positive trends, careful attention to capital expenditures is advised to maintain free cash flow growth.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	43.90B	44.32B	40.02B	27.09B	19.46B	20.56B
Gross Profit	36.18B	37.05B	32.53B	20.54B	13.62B	15.24B
EBITDA	18.48B	21.44B	17.51B	9.67B	2.60B	6.07B
Net Income	15.39B	18.85B	13.88B	7.15B	1.70B	4.41B
Balance Sheet
Total Assets	104.30B	86.31B	69.06B	56.57B	51.09B	47.92B
Cash, Cash Equivalents and Short-Term Investments	40.77B	24.97B	17.78B	11.25B	7.60B	8.18B
Total Debt	2.61B	2.79B	3.86B	1.76B	4.32B	2.84B
Total Liabilities	17.76B	10.19B	10.53B	-34.80B	8.46B	6.68B
Stockholders Equity	86.50B	76.07B	58.53B	48.74B	42.64B	41.22B
Cash Flow
Free Cash Flow	10.10B	14.28B	8.72B	6.43B	-1.96B	442.00M
Operating Cash Flow	11.91B	16.97B	12.12B	8.49B	465.00M	2.99B
Investing Cash Flow	-11.89B	-14.14B	-10.33B	-4.77B	-53.00M	-1.03B
Financing Cash Flow	-765.00M	-2.11B	-2.47B	-3.63B	348.00M	-1.86B

NATCO Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 893.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATCOPHARM, the sentiment is Neutral. The current price of 893.35 is below the 20-day moving average (MA) of 958.88, below the 50-day MA of 896.06, and above the 200-day MA of 885.89, indicating a neutral trend. The MACD of 26.10 indicates Positive momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 27.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:NATCOPHARM.

NATCO Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	76 Outperform	₹171.50B	26.69	―	0.57%	-3.79%	-20.88%
MARKSANS	71 Outperform	₹76.11B	18.03	―	0.44%	14.80%	1.35%
RAINBOW	66 Neutral	₹114.11B	46.21	―	0.22%	9.91%	9.57%
JUBLPHARMA	62 Neutral	₹136.46B	76.03	―	0.46%	10.09%	-19.40%
GLENMARK	53 Neutral	₹617.02B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

NATCO Pharma Limited Corporate Events

Natco Pharma plays down impact of Eris semaglutide deal after NSE query

Natco Pharma has clarified to the National Stock Exchange that its partnership with Eris Lifesciences for the weight-loss drug semaglutide follows the recent approval of the product by the Central Drugs Standard Control Organisation in India. The company said it is working with multiple marketing partners to launch semaglutide in March 2026 and characterized the Eris tie-up as part of its ordinary course of business with no material impact on operations.

Responding to the exchange’s surveillance query, Natco stated it is not aware of any undisclosed information that could explain trading movements in its shares. The company also noted that the media article on the Eris deal currently has no material financial impact and reiterated that it continues to comply with disclosure requirements under SEBI’s Listing Obligations and Disclosure Regulations.

NATCO Pharma Publishes Postal Ballot Notice in Newspapers and Online

NATCO Pharma Limited has notified the stock exchanges that it has published a notice of postal ballot in the newspapers Financial Express and Nava Telangana on February 21, 2026, in line with Regulation 47 of SEBI’s Listing Obligations and Disclosure Requirements. The company stated that copies of these publications, relating to the shareholder postal ballot process, are available on its website, underscoring compliance with disclosure norms and transparent communication with investors.

The disclosure highlights NATCO Pharma’s adherence to regulatory requirements and formal communication channels with its shareholders through both print and digital platforms. By publicizing the postal ballot notice in leading newspapers and hosting the material online, the company reinforces governance standards and facilitates informed participation of investors in corporate decision-making.